Clinicopathological and prognostic value of long noncoding RNA SNHG7 in cancers: a meta-analysis and bioinformatics

Wang, June; Du, Shenlin; Wang, Chen; Zhu, Zinian; Xie, Baocheng; Zhang, Bashan

doi:10.18632/aging.203650

Cited by 3 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing evidence suggests that abnormal lncRNA expression is related to human cancers, and dysregulation of lncRNAs contributes to tumor development by promoting cell proliferation, invasion and metastasis of tumor cells ( 50 , 51 ). Some studies have reported that lncRNAs,such as LUCAT1 ( 52 ), SNHG7 ( 53 ), TP73-AS1 ( 54 ), are promising to be the potential therapeutic targets and biomarkers for diagnosis, prognostic evaluation or treatment. The prognostic value of HOXA-AS2 expression levels for cancers are unclear, and the underlying mechanism has yet to be elucidated.…”

Section: Discussionmentioning

confidence: 99%

HOXA-AS2 may predict the prognosis of solid tumors among Chinese patients: A meta-analysis and bioinformatic analysis

Wang

Zhang²,

Deng³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundHOXA cluster antisense RNA 2 (lncRNA HOXA-AS2) is a long noncoding RNA (lncRNA) that aberrantly expressed in various cancers and is closely associated with cancer progression. To overcome the limitation of small sample sizes that are inherent to single studies, a meta-analysis was conducted to explore the relationship between the expression level of HOXA-AS2 and cancer prognosis.MethodsCorrelational studies were retrieved by searching the databases of PubMed, Embase and Web of Science (up to August 10, 2022). The survival and prognosis data included overall survival (OS), and clinical parameters were gathered and analyzed.ResultsEighteen publications with 1181 patients who were diagnosed with solid tumors were ultimately included. The results showed that, compared with patients with low HOXA-AS2 expression, patients with high HOXA-AS2 expression tended to have poorer overall survival (OS) (HR= 2.52, 95% CI 1.87-3.38, P < 0.01) and shorter disease-free survival (DFS) (HR=7.19, 95% CI 3.20-16.17, P < 0.01). In addition, elevated HOXA-AS2 expression indicated a larger tumor size (OR =2.43, 95% CI 1.53–3.88,P < 0.01), more advanced TNM stage (OR=3.85, 95% CI 2.79-5.31, P < 0.01), earlier lymph node metastasis (LNM) (OR = 4.41, 95% CI 3.05-6.39, P < 0.01) and distant metastasis (DM) (OR= 2.96, 95% CI 1.87-4.7, P < 0.01). Furthermore, HOXA-AS2 expression was notassociated with age (OR=1.15, 95% CI 0.90-1.47), gender (OR=1.16, 95% CI 0.89-1.53), or tumor differentiation (OR=1.21, 95% CI 0.56-2.63). Moreover, aberrant HOXA-AS2 expression was related to drug sensitivity in various types of cancers.ConclusionThe overexpression of HOXA-AS2 predicted poor cancer prognosis in the Chinese population, including poor OS, DFS, TNM, LNM, and DM. HOXA-AS2 could serve as a promising prognostic biomarker and therapeutic target.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42022352604.

show abstract

Section: Discussionmentioning

confidence: 99%

HOXA-AS2 may predict the prognosis of solid tumors among Chinese patients: A meta-analysis and bioinformatic analysis

Wang

Zhang²,

Deng³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The aberrant expression of lncRNAs has been frequently observed in a variety of diseases, including human malignancies (Isin and Dalay, 2015;Bhan et al, 2017;Bian et al, 2021;Homayoonfal et al, 2021;Liu and Lei, 2021). Moreover, an increasing number of studies have shown that lncRNAs are involved in the pathogenesis and development of many cancers and are associated with different clinicopathological features (Wang et al, 2021b;Dong et al, 2021;Ma et al, 2021;Zhou et al, 2021). For example, overexpression of the lncRNA MCM3AP-AS1 (Wang et al, 2019b) has been shown to modulate hepatocellular carcinoma (HCC) occurrence and progression and is strongly correlated with advanced tumor grade and stage, large tumor size, and poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

The LncRNA DUXAP10 Could Function as a Promising Oncogene in Human Cancer

Zhao

Dong

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cancer is one of the most prevalent and deadliest diseases globally, with an increasing morbidity of approximately 14 million new cancer cases per year. Identifying novel diagnostic and prognostic biomarkers for cancers is important for developing cancer therapeutic strategies and lowering mortality rates. Long noncoding RNAs (lncRNAs) represent a group of noncoding RNAs of more than 200 nucleotides that have been shown to participate in the development of human cancers. The novel lncRNA DUXAP10 was newly reported to be abnormally overexpressed in several cancers and positively correlated with poor clinical characteristics of cancer patients. Multiple studies have found that DUXAP10 widely regulates vital biological functions related to the development and progression of cancers, including cell proliferation, apoptosis, invasion, migration, and stemness, through different molecular mechanisms. The aim of this review was to recapitulate current findings regarding the roles of DUXAP10 in cancers and evaluate the potential of DUXAP10 as a novel biomarker for cancer diagnosis, treatment, and prognostic assessment.

show abstract

Targeting notch-related lncRNAs in cancer: Insights into molecular regulation and therapeutic potential

Siddique,

Gupta,

MGM

et al. 2024

Pathology - Research and Practice

View full text Add to dashboard Cite

Clinicopathological and prognostic value of long noncoding RNA SNHG7 in cancers: a meta-analysis and bioinformatics

Cited by 3 publications

References 43 publications

HOXA-AS2 may predict the prognosis of solid tumors among Chinese patients: A meta-analysis and bioinformatic analysis

HOXA-AS2 may predict the prognosis of solid tumors among Chinese patients: A meta-analysis and bioinformatic analysis

The LncRNA DUXAP10 Could Function as a Promising Oncogene in Human Cancer

Targeting notch-related lncRNAs in cancer: Insights into molecular regulation and therapeutic potential

Contact Info

Product

Resources

About